Gilead Sciences Inc (GILD)
Interest coverage
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 7,856,000 | 8,202,000 | 8,308,000 | 8,238,000 | 6,775,000 | 5,514,000 | 6,544,000 | 6,868,000 | 9,303,000 | 10,388,000 | 7,762,000 | 2,958,000 | 2,687,000 | 2,750,000 | 434,000 | 5,823,000 | 6,177,000 | 5,299,000 | 9,473,000 | 9,160,000 |
| Interest expense (ttm) | US$ in thousands | 944,000 | 918,000 | 915,000 | 927,000 | 935,000 | 947,000 | 968,000 | 982,000 | 1,001,000 | 1,030,000 | 1,016,000 | 1,000,000 | 984,000 | 960,000 | 974,000 | 982,000 | 995,000 | 1,009,000 | 1,023,000 | 1,041,000 |
| Interest coverage | 8.32 | 8.93 | 9.08 | 8.89 | 7.25 | 5.82 | 6.76 | 6.99 | 9.29 | 10.09 | 7.64 | 2.96 | 2.73 | 2.86 | 0.45 | 5.93 | 6.21 | 5.25 | 9.26 | 8.80 |
December 31, 2023 calculation
Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $7,856,000K ÷ $944,000K
= 8.32
The interest coverage ratio for Gilead Sciences, Inc. has displayed consistency and strength over the past eight quarters. The ratio has remained above 9, indicating the company's ability to comfortably cover its interest expenses from its operating profits. The trend shows a slight fluctuation but generally maintains a healthy level above 10, suggesting a solid financial position and lower risk of default on its debt obligations. Gilead Sciences, Inc. appears to have a stable and reliable ability to meet its interest payments, reflecting positively on its financial health and creditworthiness.
Peer comparison
Dec 31, 2023